A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 4, 2016

Primary Completion Date

June 11, 2020

Study Completion Date

December 31, 2020

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

pembrolizumab

200 mg IV given every three weeks

Trial Locations (1)

Hillman Cancer Center, Pittsburgh

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Michael Boyiadzis

OTHER

NCT02708641 - A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML | Biotech Hunter | Biotech Hunter